Carga del cáncer de próstata en Colombia (2015-2022): un análisis nacional basado en DALYs por región y grupo de edad
| dc.contributor.advisor | Rico Mendoza, Alejandro | |
| dc.contributor.author | Rodríguez Villamil, César Alonso | |
| dc.contributor.orcid | Rico Mendoza Alejandro [0000-0002-4291-6135] | |
| dc.contributor.orcid | Porras Ramírez Alexandra [0000-0002-0800-1388] | |
| dc.date.accessioned | 2025-07-22T19:56:45Z | |
| dc.date.available | 2025-07-22T19:56:45Z | |
| dc.date.issued | 2025-07 | |
| dc.description.abstract | Propósito: El cáncer de próstata es una de las principales causas de mortalidad y morbilidad de cáncer en Colombia. Este estudio tiene como objetivo estimar la carga de enfermedad por cáncer de próstata medida en Años de Vida Perdidos por Discapacidad (DALYs) en Colombia en el periodo comprendido entre 2015 a 2022, siendo el primero que realiza esta estimación por departamento. Métodos: Se estimaron los DALYs por año y departamento mediante una plantilla en Microsoft Excel, que realiza la sumatoria de los Años de Vida Perdidos por Muerte Prematura (YLLs) y los Años de Vida con Discapacidad (YLDs). Los YLLs se calcularon a partir de las tasas de mortalidad (por 1.000 hombres) con las muertes y la población publicadas por el Departamento Administrativo Nacional de Estadística (DANE), utilizando la esperanza de vida para los hombres de Japón. Los YLDs se calcularon a partir de la prevalencia (por 1.000 hombres) con los casos reportados en el Sistema Integrado de Información de la Protección Social (SISPRO) y la población mencionada previamente para los YLDs, considerando un peso de discapacidad de 0,270 y duración de la enfermedad de 10 años. Resultados: Se calcularon un total de 815.297,37 DALYs con una tasa de 34,6 DALYs por cada 1.000 hombres en todo Colombia durante el periodo 2015 a 2022. Los grupos de edad que presentaron la mayor carga fueron los de >80 años (448,6 por 1.000 hombres), seguidos de los de 70-79 (380,6) y 60-69 (146,8). Se obtuvo una tasa para todo el periodo en Colombia de 34,6 DALYs por 1.000 hombres. Los departamentos con las mayores tasas de mortalidad por 1.000 hombres fueron: Valle del Cauca (48,9), Antioquia (46,4), Risaralda (45,7), Bogotá (44,1) y Quindío (43,7); mientras que Vaupés (2,7), Guainía (4,8), Amazonas (5,3), Guaviare (6,5) y Vichada (6,7) presentaron el menor impacto. Conclusiones: El cáncer de próstata es una de las principales causas de DALYs en hombres mayores en Colombia, mostrando un aumento progresivo de la tasa nacional en el periodo 2015-2022. La mortalidad se mantiene estable, pero la carga por discapacidad es elevada. Los departamentos más afectados (Valle del Cauca, Antioquia, Bogotá, Risaralda y Quindío) concentran casi la mitad de la carga nacional, mientras que las regiones amazónicas y del oriente presentan posibles subregistros, lo que puede deberse a una limitada infraestructura sanitaria. | |
| dc.description.abstractenglish | Purpose: Prostate cancer is one of the leading causes of cancer mortality and morbidity in Colombia. This study aims to estimate the burden of prostate cancer, measured in Years of Life Lost due to Disability (DALYs), in Colombia from 2015 to 2022. It is the first study to estimate this by department. Methods: DALYs were estimated by year and department using a Microsoft Excel template, which sums the Years of Life Lost due to Premature Death (YLLs) and Years of Life with Disability (YLDs). YLLs were calculated from mortality rates (per 1,000 men) with deaths and population published by the National Administrative Department of Statistics (DANE), using life expectancy for men in Japan. YLDs were calculated based on prevalence (per 1,000 men) with cases reported in the Integrated Social Protection Information System (SISPRO) and the population previously mentioned for YLDs, considering a disability weight of 0.270 and a disease duration of 10 years. Results: A total of 815,297.37 DALYs were calculated, with a rate of 34.6 DALYs per 1,000 men across Colombia during the period 2015 to 2022. The age groups with the highest burden were those over 80 years (448.6 per 1,000 men), followed by those 70-79 (380.6) and 60-69 (146.8). A rate of 34.6 DALYs per 1,000 men was obtained for the entire period in Colombia. The departments with the highest mortality rates per 1,000 men were: Valle del Cauca (48.9), Antioquia (46.4), Risaralda (45.7), Bogotá (44.1), and Quindío (43.7); while Vaupés (2.7), Guainía (4.8), Amazonas (5.3), Guaviare (6.5), and Vichada (6.7) had the lowest impact. Conclusions: Prostate cancer is one of the leading causes of DALYs in older men in Colombia, with the national rate showing a progressive increase in the 2015-2022 period. Mortality remains stable, but the disability burden is high. The most affected departments (Valle del Cauca, Antioquia, Bogotá, Risaralda, and Quindío) account for almost half of the national burden, while the Amazon and eastern regions may have underreporting, which may be due to limited health infrastructure. Keywords: DALYs, prostate cancer, burden of disease. | |
| dc.description.degreelevel | Maestría | spa |
| dc.description.degreename | Magíster en Epidemiología | spa |
| dc.format.mimetype | application/pdf | |
| dc.identifier.instname | instname:Universidad El Bosque | spa |
| dc.identifier.reponame | reponame:Repositorio Institucional Universidad El Bosque | spa |
| dc.identifier.repourl | repourl:https://repositorio.unbosque.edu.co | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12495/15023 | |
| dc.language.iso | es | |
| dc.language.iso | en | |
| dc.publisher.faculty | Facultad de Medicina | spa |
| dc.publisher.grantor | Universidad El Bosque | spa |
| dc.publisher.program | Maestría en Epidemiología | spa |
| dc.relation.references | 1. Chu F, Chen L, Guan Q, Zujie C, Ji Q, Ma Y, et al. Global burden of prostate cancer: ageperiod cohort analysis from 1990 to 2021 and projections until 2040. World Journal of Surgical Oncology. 2025; 23(98): p. 12. | |
| dc.relation.references | 2. Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: p. 209-249. | |
| dc.relation.references | 3. Schafer E, Laversanne M, Sung H, Soerjomataramb I, Briganti A, Dahut W, et al. Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update. Eur Urol. 2025; 87(3): p. 302-313. | |
| dc.relation.references | 4. Torres-Roman J, Valcarcel B, Arce-Huamani M, Simbaña-Rivera K, Salvador-Carrillo J, Poterico J, et al. Prostate cancer in Latin America and the Caribbean: mortality trends from 1997 to 2017 and predictions to 2030. Salud Pública Mex. 2024; 66: p. 226-235. | |
| dc.relation.references | 5. de Vries E, Gallego A, Gil F. Trends in cancer mortality in the elderly and oldest old in South America. Cancer Epidemiology. 2025; 95: p. 102761. | |
| dc.relation.references | 6. Guzman-Esquivel J, Murillo-Zamora E, Ortiz-Mesina M, Galvan-Salazar H, De-LeonZaragoza L, Casarez-Price J, et al. Regional and national burden of prostate cancer: incidence, mortality, years of life lost, and disability-adjusted life years, in Mexico and Latin America from 1990 to 2019. Int Urol Nephrol. 2023; 3: p. 1-6. | |
| dc.relation.references | 7. Mejia E, Lewis A, Garcés-Palacio I, Hernandez D, Chamberlain R, Soliman A. Relationship between universal health insurance benefits and prostate cancer mortality in Colombia. BMC Public Health. 2024; 24: p. 2667. | |
| dc.relation.references | 8. Cuenta de Alto Costo. Una mirada al cáncer de próstata en Colombia. [Online].; 2021 [cited 2025 April 11. Available from: https://cuentadealtocosto.org/cancer/una-miradaal-cancer-de-prostata-en-colombia/. | |
| dc.relation.references | 9. Parra-Medina R, Barahona-Correa J, Chaves J, Páyan-Gomez C, Ramirez-Clavijo S, Fernández Ávila D, et al. Prevalence and Demographic Characteristics of Prostate Cancer Patients in Colombia: data from the National Health Registry from 2015 to 2019. Colombian Urology Journal. 2021; 30(3): p. 204-209. | |
| dc.relation.references | 10. Mignozzi S, Santucci C, Levi F, Malvezzi M, Boffetta P, Corso G, et al. Cancer mortality predictions for 2025 in Latin America with focus on prostate cancer. European Journal of Cancer Prevention. 2025;: p. 10.1097. | |
| dc.relation.references | 11. Safiri S, Shamekh A, Hassanzadeh K, Fazlollahi A, Sullman M, Raeisi M, et al. The burden of prostate cancer in the North Africa and Middle East Region from 1990 to 2021. Sci Rep. 2025; 15(1): p. 1853. | |
| dc.relation.references | 12. Gomez de la Rosa F, Carrasquilla-Sotomayor M, Alvis-Zakzuk N, Alfonso Quiñones P, Romero Prada M, Alvis-Guzmán N. Prostate Cancer Costs In Colombia: A Top-Down Approach. Value in Health. 2018; 21(1): p. S25. | |
| dc.relation.references | 13. Cantarero-Prieto D, Lera J, Lanza-Leon P, Barreda-Gutierrez M, Guillem-Porta V, CasteloBranco L, et al. The Economic Burden of Localized Prostate Cancer and Insights Derived from Cost Effectiveness Studies of the Different Treatments. Cancers. 2022; 14: p. 4088. | |
| dc.relation.references | 14. Murray C, Lopez A. Evidence-Based Health Policy - Lessons from the Global Burden of Disease Study. Science. 1996; 274(5288): p. 740-743. | |
| dc.relation.references | 15. WHO. WHO methods and data sources for global burden of disease estimates 2000-2019: Global Health Estimates Technical Paper WHO/ DDI/DNA/GHE/2020.3. Geneva: World Health Organization, Department of Data and Analytics, Division of Data, Analytics and Delivery for Impact; 2020. | |
| dc.relation.references | 16. Murray C, Lopez A, Black R, Mathers C, Shibuya K, Ezzati M, et al. Global Burden of Disease 2005: call for collaborators. Lancet. 2007; 370(9582): p. 109-110. | |
| dc.relation.references | 17. Murray C, Lopez A, Mathers C, Stein C. The Global Burden of Disease 2000 project: aims, methods and data sources. World Health Organization, Global Programme on Evidence for Health Policy Discussion Paper No. 36; 2001. | |
| dc.relation.references | 18. Murray C, Vos T, Lozano R, Naghavi M, Flaxman A, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): p. 2197–223. | |
| dc.relation.references | 19. Departamento Administrativo Nacional de Estadística - DANE. Metadatos y Microdatos Anonimizados. [Online]. [cited 2024 february 10. Available from: https://microdatos.dane.gov.co/index.php/catalog/central/about. | |
| dc.relation.references | 20. Costilla R, Tobias M, Blakely T. The burden of cancer in New Zealand: a comparison of incidence and DALY metrics and its relevance for ethnic disparities. Aust N Z J Public Health. 2013; 37: p. 218-225. | |
| dc.relation.references | 21. Soerjomataram I, Lortet-Tieulent J, Ferlay J, Forman D, Mathers C, Parkin DM, et al. Estimating and validating disability-adjusted life years at the global level: a methodological framework for cancer. BMCMedicalResearchMethodology. 2012;12(125): p. 1-15. | |
| dc.relation.references | 22. Nossiter J, Morris M, Parry M, Sujenthiran A, Cathcart P, der Meulen J, et al. Impact of the COVID-19 pandemic on the diagnosis and treatment of men with prostate cancer. BJU Int. 2022; 130: p. 262–270. | |
| dc.relation.references | 23. Suter F, Wanner M, Wicki A, Korol D, Rohrmann S. Effect of the COVID-19 pandemic and lockdown on cancer stage distribution and time to treatment initiation using cancer registry data of the Swiss cantons of Zurich and Zug from 2018 to 2021. Journal of Cancer Research and Clinical Oncology. 2025; 151(88). | |
| dc.relation.references | 24. Johansson A, Skog A, Johannesen T, Myklebust T, Kønig S, Skovlund , et al. Changes in cancer incidence and stage during the COVID-19 pandemic in 2020–2021 in the Nordic countries. Acta Oncol. 2025; 12(64): p. 257-266. | |
| dc.relation.references | 25. Szkudlarek D, Kalinowska K, Wiatrak B. Impact of the COVID-19 Pandemic on Histopathological Cancer Diagnostics in Lower Silesia: A Comparative Analysis of Prostate, Breast, and Colorectal Cancer from 2018 to 2022. Cancers. 2025; 17(1): p. 134. | |
| dc.relation.references | 26. Liu D, Zhou L, Youyou L, Liu J, Zhou L, Tang J, et al. Endocrine cancer trends 1990–2021:global disparities and health inequalities. Endocrine-Related Cancer. 2024; 31(11). | |
| dc.relation.references | 27. Zhai Z, Zheng Y, Li N, Deng Y, Zhou L, Tian T, et al. Incidence and Disease Burden of Prostate Cancer From 1990 to 2017: Results From the Global Burden of Disease Study 2017. Cancer. 2020; 126(9): p. 1969-1978. | |
| dc.relation.references | 28. Instituto Nacional de Cancerología. Manual para la Detección Temprana del Cáncer de Próstata Bogotá; 2015. | |
| dc.relation.references | 29. Rubens M, Appunni S, Saxena A, Ramamoorthy V, Khosla A, McGranaghan P, et al. Trend and burden of adult cancer-related hospitalizations in the United States. Sci Rep. 2025; 15(1): p. 13388. | |
| dc.relation.references | 30. Roehrborn C, Black L. The economic burden of prostate cancer. BJU Int. 2011;: p. 806-813. | |
| dc.relation.references | 31. Liu PC, Lin YS, Ou YC, Hsu CY, Tung MC, Chiu YM. Comprehensive analysis of prostate cancer life expectancy, loss of life expectancy, and healthcare expenditures: Taiwan national cohort study spanning 2008 to 2019. PloS One. 2025; 20(4): p. e0310613. | |
| dc.relation.references | 32. Michel K, Slinger M, Guzzo T, Malkowicz B, Chhatre S, Jayadevappa R. Beyond Medical Bills: The Indirect Costs of Prostate Cancer. Urol Pract. ; 12(1): p. 94-102. | |
| dc.relation.references | 33. de Vries E, Vergara-García O, Karduss-Preciado S, Baquero V, Prieto S, Sánchez M, et al. The financial impact of a terminal cancer on patient′s families in Colombia – A survey study. Journal of Cancer Policy. 2021; 28: p. 100272. | |
| dc.relation.references | 34. Chen J, Meng C. Burden of Urological Cancers in the Labour Force from 1990 to 2021 and Projections to 2050. Ann Surg Oncol. 2025. | |
| dc.relation.references | 35. Jayadevappa R, Schwartz S, Chhatre S, Gallo J, Wein A, Malkowicz B. The burden of outof pocket and indirect costs of prostate cancer. Prostate. 2010; 70(11): p. 1255-1264. | |
| dc.relation.references | 36. Hanly P, Sharp L. The cost of lost productivity due to premature cancer-related mortality: an economic measure of the cancer burden. BMC Cancer. 2014; 14(224): p. 1-10. | |
| dc.relation.references | 37. Sanabria A, Martínez J, Díaz J. Cáncer de colon: análisis del costo de enfermedad para los estadios III y IV en Cansercoop IPS. Rev. Colomb. Cienc. Quím. Farm. 2009; 38(2): p.193-214. | |
| dc.relation.references | 38. Pardo C, de Vries E, Buitrago L, Gamboa Ó. Atlas de mortalidad por cáncer en Colombia. Bogotá D.C.: Instituto Nacional de Cancerología; 2017. | |
| dc.relation.references | 39. DANE. Resultados para población negra, afrodescendiente, raizal y palenquera - Encuesta Nacional de Calidad de Vida (ECV) 2023. Boletín técnico. Bogotá:; 2024. | |
| dc.relation.references | 40. Borda M, David-Pardo D, Ríos-Zuluaga J, López-Zea A, Forero-Borda L, Gutiérrez S, et al. Asociación entre tamización de cáncer de próstata, vinculación al sistema de salud y factores asociados en adultos mayores: análisis secundario de la encuesta SABE Bogotá, Colombia. Revista Urología Colombiana. 2018; 27(1): p. 35-41. | |
| dc.relation.references | 41. Bravo L, Muñoz N. Epidemiología del cáncer en Colombia. Colombia Médica. 2018;49(1): p. 9-12. | |
| dc.relation.references | 42. de Vries E, Buitrago G, Quitian H, Wiesner C, Castillo J. Access to cancer care in Colombia, a middle-income country with universal health coverage. Journal of Cancer Policy. 2018; 15(part B): p. 104-112. | |
| dc.relation.references | 43. Henríquez-Mendoza G, Wiesner-Ceballos C. El cáncer es un problema prioritario en salud pública en Colombia: se necesita un nuevo plan para su control, específico y vinculante para el sistema de salud colombiano. Rev Colomb Cancero. 2024; 28(4): p.136-138. | |
| dc.rights | Attribution-NonCommercial-ShareAlike 4.0 International | en |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.accessrights | https://purl.org/coar/access_right/c_abf2 | |
| dc.rights.local | Acceso abierto | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | |
| dc.subject | DALYs | |
| dc.subject | Cáncer de próstata | |
| dc.subject | Carga de enfermedad | |
| dc.subject.keywords | DALYs | |
| dc.subject.keywords | Prostate cancer | |
| dc.subject.keywords | burden of disease | |
| dc.subject.nlm | WA 105 | |
| dc.title | Carga del cáncer de próstata en Colombia (2015-2022): un análisis nacional basado en DALYs por región y grupo de edad | |
| dc.title.translated | Burden of prostate cancer in Colombia (2015-2022): a national analysis based on DALYs by region and age group | |
| dc.type.coar | https://purl.org/coar/resource_type/c_bdcc | |
| dc.type.coarversion | https://purl.org/coar/version/c_ab4af688f83e57aa | |
| dc.type.driver | info:eu-repo/semantics/masterThesis | |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | |
| dc.type.local | Tesis/Trabajo de grado - Monografía - Maestría | spa |